Paclitaxel

目录号:S1150 别名: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。

规格 价格 库存 购买数量  
RMB 749.07 现货
RMB 571.49 现货
RMB 2235.46 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

  • Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Paclitaxel是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。
特性 Paclitaxel 是有丝分裂抑制剂。
靶点
Microtubule (human endothelial cells) [1]
0.1 pM
体外研究

Paclitaxel在104到 105倍更高浓度时,抑制非内皮性人类细胞,IC50 为1 nM -10 nM。Paclitaxel选择性抑制细胞增殖,具有种属特异性,在Paclitaxel极低浓度时,小鼠内皮细胞对 Paclitaxel不敏感。 极低浓度Paclitaxel抑制 人类内皮细胞,但是不影响细胞微管结构,且处理的细胞在 G2/M 期没有出现细胞周期停滞和凋亡,说明这是一种新型尚未查明的作用机制。在体外血管生成实验中,在三维纤维蛋白基质中,极低浓度Paclitaxel阻断人类内皮细胞形成芽管。[1] 在SMF存在时, Paclitaxel 作用于 K562 细胞的有效浓度从50 ng/ml降低到 10 ng/ml。在有或无SMF时,Paclitaxel 使K562 细胞周期停滞与DNA损伤相关。[2] Paclitaxel单独处理四种细胞系,包括A549 细胞,H358, H1395 细胞和H1666 细胞,抑制CDK1,这种作用存在时间依赖性。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DGUGlEPTB;MD6wNFAzQDdizszN NHO2RW9USU6JRWK=
LC-2-ad M2P2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzwVHo{UUN3ME2wMlAxODNzNzFOwG0> NVnNfGtoW0GQR1XS
RL95-2 NUPP[Yo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPaTWM2OD1yLkCwNFY3QCEQvF2= MVzTRW5ITVJ?
MZ1-PC MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HPOGlEPTB;MD6wNFA4OjlizszN NUC3[VFEW0GQR1XS
TE-8 NXrKS4VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljmTWM2OD1yLkCwNVE4KM7:TR?= MYPTRW5ITVJ?
SW954 NUXNV5Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMECxNVkh|ryP MVvTRW5ITVJ?
TE-11 M4\sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLWUHRKSzVyPUCuNFAyOjNizszN NHzrcWFUSU6JRWK=
PSN1 NVHLe4dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfv[5lRUUN3ME2wMlAxOTNizszN M3ewPXNCVkeHUh?=
MOLT-4 M3TscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMECxOFkh|ryP NEXhRmlUSU6JRWK=
697 M3X6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMECxOUDPxE1? M4Lmd3NCVkeHUh?=
ETK-1 NXTVcnJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\ETWM2OD1yLkCwNVUzKM7:TR?= MmPUV2FPT0WU
TE-10 MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HCXmlEPTB;MD6wNFE2PCEQvF2= M1rNSHNCVkeHUh?=
HUTU-80 M4rFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLGTWM2OD1yLkCwNVY5KM7:TR?= M4LDPXNCVkeHUh?=
NTERA-S-cl-D1 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTZTWM2OD1yLkCwNlA6KM7:TR?= NWXsXmU6W0GQR1XS
MFH-ino M1;aeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\md217UUN3ME2wMlAxOjZ6IN88US=> Mn3EV2FPT0WU
IA-LM NGfFTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn0TWM2OD1yLkCwNlgh|ryP M{j1bnNCVkeHUh?=
MC116 NWjRT5ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLNTWM2OD1yLkCwNlg6KM7:TR?= NGi4WGtUSU6JRWK=
RKO MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILqboRKSzVyPUCuNFAzQThizszN MWLTRW5ITVJ?
MRK-nu-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkftTWM2OD1yLkCwNlk6KM7:TR?= MlThV2FPT0WU
VA-ES-BJ NYHEVY04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMECzJO69VQ>? MW\TRW5ITVJ?
KALS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMECzNFgh|ryP MWrTRW5ITVJ?
BB30-HNC M2DYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TiPWlEPTB;MD6wNFMyPCEQvF2= MmnCV2FPT0WU
ACN NVTmeYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT6TWM2OD1yLkCwN|E3KM7:TR?= MUnTRW5ITVJ?
TE-9 NXTCNXU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TIdmlEPTB;MD6wNFMzPiEQvF2= Ml65V2FPT0WU
SIG-M5 NIDNWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm4TWM2OD1yLkCwN|I4KM7:TR?= NVvHbZhHW0GQR1XS
no-10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvy[INJUUN3ME2wMlAxOzZ{IN88US=> MXTTRW5ITVJ?
EW-1 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMECzO|Eh|ryP Mo\BV2FPT0WU
SK-LMS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\3eJVCUUN3ME2wMlAxPDBzIN88US=> MXHTRW5ITVJ?
GT3TKB MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEC0N|Qh|ryP NEe4dIVUSU6JRWK=
ES4 M1WyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEC0OFkh|ryP MlrtV2FPT0WU
IMR-5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkexTWM2OD1yLkCwOFUh|ryP NGD2SZlUSU6JRWK=
NCI-H1648 MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEC0Olkh|ryP NUe2RZk2W0GQR1XS
MV-4-11 NGrvNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly2TWM2OD1yLkCwOFc2KM7:TR?= MV3TRW5ITVJ?
SK-UT-1 M2\kfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ntXGlEPTB;MD6wNFQ5KM7:TR?= NY\5bIZ6W0GQR1XS
NB13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDXTWM2OD1yLkCwOFkyKM7:TR?= MWDTRW5ITVJ?
DJM-1 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7IRmZKSzVyPUCuNFA2OyEQvF2= NGLNN5JUSU6JRWK=
ES8 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz4bYp{UUN3ME2wMlAxPTN6IN88US=> MXHTRW5ITVJ?
TE-6 NXj2XlE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTnTWM2OD1yLkCwOVch|ryP MUjTRW5ITVJ?
KS-1 NVvIVoRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\6XWlEPTB;MD6wNFU5OiEQvF2= M{D2ZnNCVkeHUh?=
TE-1 NY\Ob4NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEC2NFYh|ryP NYLudZpUW0GQR1XS
ATN-1 NV;rSpFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfwTWM2OD1yLkCwOlA6KM7:TR?= M3nIbHNCVkeHUh?=
A4-Fuk MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLKeWxCUUN3ME2wMlAxPjFzIN88US=> MkLIV2FPT0WU
ALL-PO M3PKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEC2N{DPxE1? M{PWZ3NCVkeHUh?=
BE-13 NGPqbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPKRpNKSzVyPUCuNFA3OzZizszN MXrTRW5ITVJ?
KM12 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ETWM2OD1yLkCwOlM4KM7:TR?= M3jLXXNCVkeHUh?=
NOS-1 MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7JTWM2OD1yLkCwOlUh|ryP NYi3UWhzW0GQR1XS
SW962 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPH[JdKSzVyPUCuNFA3PjJizszN MmnRV2FPT0WU
OCUB-M MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfteolKSzVyPUCuNFA3PjJizszN M2HrTHNCVkeHUh?=
NCI-H510A NEDkZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;yTWM2OD1yLkCwOlY2KM7:TR?= M1;sb3NCVkeHUh?=
EW-16 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMEC2PVQh|ryP MV3TRW5ITVJ?
KGN NInMXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2cmlEPTB;MD6wNFcyOiEQvF2= MWjTRW5ITVJ?
LS-411N MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf3b5ZKSzVyPUCuNFA4OTdizszN NY\0[mN7W0GQR1XS
Becker NYLLeYRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL0TWM2OD1yLkCwO|Ih|ryP NEn2[lJUSU6JRWK=
HC-1 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMEC3NlEh|ryP MXTTRW5ITVJ?
CESS MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfGTWM2OD1yLkCwO|M4KM7:TR?= Ml;ZV2FPT0WU
KURAMOCHI M2jXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEC3OFgh|ryP NH;G[I9USU6JRWK=
TGBC24TKB M{PKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PCeGlEPTB;MD6wNFc2OiEQvF2= M2njdXNCVkeHUh?=
SW982 NELRT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfxNVdKSzVyPUCuNFA4PjZizszN MnrIV2FPT0WU
HCE-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEC3Olch|ryP MYjTRW5ITVJ?
LOUCY MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEC3O|Uh|ryP NILmZo9USU6JRWK=
8-MG-BA NV3vZ|Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XtRWlEPTB;MD6wNFc6PiEQvF2= MYfTRW5ITVJ?
HT-144 MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzyWWpwUUN3ME2wMlAxQCEQvF2= Mn3MV2FPT0WU
LXF-289 NF;lfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr5VnhsUUN3ME2wMlAxQDF6IN88US=> MoLqV2FPT0WU
RS4-11 NET0cJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMEC4N|Yh|ryP MVrTRW5ITVJ?
DEL NF7BZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jtbWlEPTB;MD6wNFg1PSEQvF2= M3vqdnNCVkeHUh?=
OCI-AML2 MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq5WJpIUUN3ME2wMlAxQDV{IN88US=> M4\IWXNCVkeHUh?=
CCRF-CEM MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\kRoZKUUN3ME2wMlAxQDdzIN88US=> NX3BWGc6W0GQR1XS
A388 NGjjOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLENGFKSzVyPUCuNFA5PzRizszN NHz2UXdUSU6JRWK=
KNS-42 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q0UmlEPTB;MD6wNFg6OSEQvF2= M1PuZXNCVkeHUh?=
OVCAR-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrRTHlKSzVyPUCuNFA6ODRizszN MWTTRW5ITVJ?
NCI-H1355 NHv3N45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{WzVWlEPTB;MD6wNFkyPCEQvF2= M2DyWnNCVkeHUh?=
BL-70 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\oTWM2OD1yLkCwPVMh|ryP MWjTRW5ITVJ?
BL-41 NYPDbGVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzxT4pKSzVyPUCuNFA6OzRizszN NUXpWFJuW0GQR1XS
A101D MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEC5OkDPxE1? NFzMN4NUSU6JRWK=
HL-60 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUiyS25FUUN3ME2wMlAxQTZ4IN88US=> Mmj6V2FPT0WU
COR-L279 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PwWGlEPTB;MD6wNFk6QSEQvF2= MVjTRW5ITVJ?
NCI-SNU-16 NYnTPWhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPlWXJKSzVyPUCuNFExODhizszN MYnTRW5ITVJ?
Calu-6 NIT2[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjLO4x[UUN3ME2wMlAyODF{IN88US=> MWrTRW5ITVJ?
SR NF;oZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITNT3BKSzVyPUCuNFExOjZizszN MmfsV2FPT0WU
QIMR-WIL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEGwN|Mh|ryP MUfTRW5ITVJ?
LB647-SCLC Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPFTWM2OD1yLkCxNFUyKM7:TR?= NFrZe25USU6JRWK=
RPMI-8226 M2HD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEGxNFIh|ryP NV3WWJU2W0GQR1XS
SK-PN-DW NVXIUVVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEGxNVIh|ryP M{Gyc3NCVkeHUh?=
SF268 NIDEcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfJTWM2OD1yLkCxNVUyKM7:TR?= NEPlZ3pUSU6JRWK=
HD-MY-Z NVf3Z5EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jye2lEPTB;MD6wNVE3OyEQvF2= MlHqV2FPT0WU
DOHH-2 NUDyVWViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHQTWM2OD1yLkCxNlA{KM7:TR?= M1PKOXNCVkeHUh?=
SCC-3 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEGyNFQh|ryP NWfV[4ZCW0GQR1XS
ST486 M3Pqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPHTWM2OD1yLkCxNlA1KM7:TR?= M1nPd3NCVkeHUh?=
NALM-6 NIO1d2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPoU2trUUN3ME2wMlAyOjF2IN88US=> MYrTRW5ITVJ?
NCI-H1436 NWfEcXV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHXTlRKSzVyPUCuNFEzOzFizszN NVrlSVh2W0GQR1XS
KE-37 NWjqRlN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jyNWlEPTB;MD6wNVI{PCEQvF2= NYrXZoxpW0GQR1XS
RPMI-8402 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TmU2lEPTB;MD6wNVI2PiEQvF2= MoLMV2FPT0WU
RXF393 M{DrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H1b2lEPTB;MD6wNVI2PyEQvF2= MYnTRW5ITVJ?
KARPAS-45 MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW4fo1KSzVyPUCuNFEzPyEQvF2= M4jsbHNCVkeHUh?=
HOP-62 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPlR3ZJUUN3ME2wMlAyOjd4IN88US=> NFHwfoNUSU6JRWK=
ES1 NUXYSWNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;TbmlKSzVyPUCuNFEzQDhizszN MVnTRW5ITVJ?
L-363 NHv2N5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjyUnNKSzVyPUCuNFE{PTFizszN NFz1S2VUSU6JRWK=
GI-1 M4PKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PUWmlEPTB;MD6wNVM4OyEQvF2= MYXTRW5ITVJ?
CTV-1 NVTGVYlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknITWM2OD1yLkCxOFc5KM7:TR?= MWjTRW5ITVJ?
TE-5 NUi1N4FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEG0PVYh|ryP NILURm5USU6JRWK=
SNU-C2B M2DhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLmW3lPUUN3ME2wMlAyPDl4IN88US=> MnfmV2FPT0WU
K-562 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HjUGlEPTB;MD6wNVUyPiEQvF2= NVuxdmdMW0GQR1XS
SNB75 NIj4N|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLGU21XUUN3ME2wMlAyPTRizszN MlmxV2FPT0WU
MOLT-13 NHvhOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMEG2N|ch|ryP M37KN3NCVkeHUh?=
LS-123 NYDPdGJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\1OGhKSzVyPUCuNFE3PjRizszN NVXpd4pCW0GQR1XS
NCI-SNU-5 NHXWSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\5ephLUUN3ME2wMlAyPzBzIN88US=> NUizdFBFW0GQR1XS
Daudi NG\sXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEG3NFgh|ryP MYrTRW5ITVJ?
A253 MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX6RpBKSzVyPUCuNFE4OzhizszN NG\xS2dUSU6JRWK=
TGBC1TKB MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jVbWlEPTB;MD6wNVc2OiEQvF2= NXzzSFhxW0GQR1XS
SJSA-1 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLK[3JKSzVyPUCuNFE4PjdizszN MULTRW5ITVJ?
NCCIT NWnaTld1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fkXmlEPTB;MD6wNVc3QSEQvF2= NWjDR5V7W0GQR1XS
NCI-H69 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMEG3O|gh|ryP NX3hPVZTW0GQR1XS
SH-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q3fmlEPTB;MD6wNVg6PSEQvF2= M4HDRnNCVkeHUh?=
HCC1187 MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ThT2lEPTB;MD6wNVkzPCEQvF2= NGHYUFNUSU6JRWK=
HCC1599 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;MUZlPUUN3ME2wMlAzODJizszN NF63ZYZUSU6JRWK=
ONS-76 MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnZTWM2OD1yLkCyNFM3KM7:TR?= NIjmeJlUSU6JRWK=
KU812 M4rLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj2TWM2OD1yLkCyNFM6KM7:TR?= Mkj2V2FPT0WU
ML-2 NF7jW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS0cWVCUUN3ME2wMlAzODR5IN88US=> Mo\tV2FPT0WU
HCE-T M4DY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEKwPVIh|ryP MmXMV2FPT0WU
NCI-H446 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEKxNVIh|ryP M1;ZVnNCVkeHUh?=
RPMI-6666 M1izZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTscFJOUUN3ME2wMlAzOTR7IN88US=> MXHTRW5ITVJ?
MOLT-16 NYD1XINVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DpSWlEPTB;MD6wNlE2OyEQvF2= NUnHZXVIW0GQR1XS
JiyoyeP-2003 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYftbWxUUUN3ME2wMlAzOTd4IN88US=> NG\KcY1USU6JRWK=
MHH-PREB-1 NFznc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli2TWM2OD1yLkCyNVkyKM7:TR?= NGjERZVUSU6JRWK=
MC-CAR MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\vTWM2OD1yLkCyN|I3KM7:TR?= M1LXNnNCVkeHUh?=
BC-3 NFrod|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMEKzOFQh|ryP Mo\tV2FPT0WU
KINGS-1 NWHsRW5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMEKzOVUh|ryP NITLemFUSU6JRWK=
PF-382 M{Ltbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHFO|FsUUN3ME2wMlAzOzd6IN88US=> M4j5UnNCVkeHUh?=
J-RT3-T3-5 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPBTWM2OD1yLkCyN|g{KM7:TR?= NVmwfmx[W0GQR1XS
SF539 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHjTWM2OD1yLkCyOFAyKM7:TR?= M3:1ZXNCVkeHUh?=
LB831-BLC NGrxSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMEK0PFUh|ryP NYHwOHE2W0GQR1XS
DMS-114 M3LGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDMZWVKSzVyPUCuNFI2ODJizszN NHLVU3lUSU6JRWK=
LB1047-RCC NGqwdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:wTWM2OD1yLkCyOVEh|ryP NVrMcVh1W0GQR1XS
LB771-HNC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC5c5BvUUN3ME2wMlAzPTN2IN88US=> NITjdVdUSU6JRWK=
BB65-RCC NEDnVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3oTWM2OD1yLkCyOVM1KM7:TR?= MYnTRW5ITVJ?
BV-173 M17ub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXtTWM2OD1yLkCyOVU1KM7:TR?= M4jGfHNCVkeHUh?=
ARH-77 NUnQTHJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z6S2lEPTB;MD6wNlYxOSEQvF2= MX;TRW5ITVJ?
IST-MEL1 NUTpe2ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fIPWlEPTB;MD6wNlYzOyEQvF2= M{P5UnNCVkeHUh?=
NB1 NYW5VVhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDvOW5KSzVyPUCuNFI3QDdizszN Ml76V2FPT0WU
EoL-1-cell MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvmTm5KSzVyPUCuNFI3QDhizszN MnTOV2FPT0WU
KY821 M{KxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvob3pJUUN3ME2wMlAzPjl5IN88US=> MlnCV2FPT0WU
CMK NIfpZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fEfWlEPTB;MD6wNlc{PCEQvF2= NInWPXVUSU6JRWK=
NCI-H2126 MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3oWFlKSzVyPUCuNFI4PjhizszN NVfjOIRKW0GQR1XS
NCI-H526 NFvSPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn1VJpKSzVyPUCuNFI5QTFizszN NXPybXBmW0GQR1XS
COLO-684 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrXXHFKSzVyPUCuNFI6ODhizszN MnjvV2FPT0WU
NCI-H747 M2fmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\iWZJKSzVyPUCuNFI6OzNizszN Mn[zV2FPT0WU
JAR NFjLbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm5TWM2OD1yLkCyPVQ3KM7:TR?= M4XQ[XNCVkeHUh?=
MEG-01 NVHNVJYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn34TWM2OD1yLkCyPVc5KM7:TR?= MnT2V2FPT0WU
MONO-MAC-6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHxTWM2OD1yLkCzNFI{KM7:TR?= NEf2V2xUSU6JRWK=
IST-SL1 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu3b3prUUN3ME2wMlA{ODR{IN88US=> MW\TRW5ITVJ?
CPC-N Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q1OWlEPTB;MD6wN|A4QSEQvF2= NVPu[GlxW0GQR1XS
NCI-H1963 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT6TWM2OD1yLkCzNVMyKM7:TR?= NUX6eGI{W0GQR1XS
K052 M2XqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC5TmdJUUN3ME2wMlA{OjR5IN88US=> M4n6eHNCVkeHUh?=
KM-H2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTQTWM2OD1yLkCzN|A4KM7:TR?= Mnv0V2FPT0WU
TE-12 NH3seGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXPTWM2OD1yLkCzN|A6KM7:TR?= M{TnWXNCVkeHUh?=
TK10 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXCO3poUUN3ME2wMlA{OzV4IN88US=> M{fBSHNCVkeHUh?=
NMC-G1 M{\DR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\wTWM2OD1yLkCzOFUzKM7:TR?= M2XLe3NCVkeHUh?=
no-11 M1:4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv5NGFvUUN3ME2wMlA{PDd6IN88US=> MWDTRW5ITVJ?
NCI-H524 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDOS5o6UUN3ME2wMlA{PTJ7IN88US=> MUHTRW5ITVJ?
MHH-CALL-2 M1;3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;5V2lEPTB;MD6wN|U3OiEQvF2= MXTTRW5ITVJ?
GB-1 NUX2XGI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMEO2JO69VQ>? M2G5cXNCVkeHUh?=
OPM-2 M1S5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEO2O|Mh|ryP NVTHPHhyW0GQR1XS
RH-1 NX\ReHV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTlc2FKSzVyPUCuNFM5OTlizszN NHz1TWpUSU6JRWK=
NCI-H64 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\nPWlEPTB;MD6wN|g2PyEQvF2= NEjRNmhUSU6JRWK=
EVSA-T M1nYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vBTWlEPTB;MD6wN|kzOyEQvF2= NV21T5pOW0GQR1XS
KARPAS-299 NEPZWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMEO5PEDPxE1? NH[2[IFUSU6JRWK=
MZ7-mel MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HLUmlEPTB;MD6wOFA1KM7:TR?= NHv2SW9USU6JRWK=
LB373-MEL-D Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TmT2lEPTB;MD6wOFExPSEQvF2= NHH6VXFUSU6JRWK=
HEL M3LOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzJTWM2OD1yLkC0NVQh|ryP NIXaPFVUSU6JRWK=
SW872 NIXXSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\UeHI{UUN3ME2wMlA1OjFizszN NYPTc3lTW0GQR1XS
DU-4475 NX[4cIg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMESyOFQh|ryP MnvNV2FPT0WU
IST-SL2 M{nIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nhZmlEPTB;MD6wOFI4PSEQvF2= M1TybnNCVkeHUh?=
NCI-H82 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMESzNFch|ryP MYfTRW5ITVJ?
LC4-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7LdHUxUUN3ME2wMlA1OzVzIN88US=> MV3TRW5ITVJ?
HDLM-2 NFKzd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jRWGlEPTB;MD6wOFM6OiEQvF2= NInFS2ZUSU6JRWK=
MMAC-SF NWr2ZWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjHTWM2OD1yLkC0OVM1KM7:TR?= NVu0fmpEW0GQR1XS
L-540 M2rUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPXeWFKSzVyPUCuNFQ3OzlizszN M4fvUXNCVkeHUh?=
MZ2-MEL M1rWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnEVldDUUN3ME2wMlA1PzR{IN88US=> NWrUcYx5W0GQR1XS
LU-134-A NFi4fIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\mTWM2OD1yLkC0O|c{KM7:TR?= M4HrWHNCVkeHUh?=
UACC-257 NVKzdo56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMES4OFkh|ryP MoDrV2FPT0WU
NCI-H1581 NEHqXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMES5OVMh|ryP Mk\rV2FPT0WU
NB17 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmyeppiUUN3ME2wMlA1QTd7IN88US=> NHLOSIVUSU6JRWK=
SBC-1 NHvsUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTRTWM2OD1yLkC1NFQzKM7:TR?= NETq[IdUSU6JRWK=
TALL-1 NY\3WWJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfDW|NKSzVyPUCuNFUxPDVizszN NFLKcXRUSU6JRWK=
NCI-H1304 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7CRYxsUUN3ME2wMlA2OjB6IN88US=> M2j4b3NCVkeHUh?=
NEC8 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fsd2lEPTB;MD6wOVI5PiEQvF2= NGnBUHhUSU6JRWK=
CAL-148 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P0UGlEPTB;MD6wOVQ{QSEQvF2= NEmyXJJUSU6JRWK=
CGTH-W-1 M3HDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEW0OFkh|ryP M{nDdnNCVkeHUh?=
NCI-H889 NWDVS2JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEW1PVIh|ryP NYrzUpV6W0GQR1XS
GR-ST MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\4TWM2OD1yLkC1OlIyKM7:TR?= M4rlN3NCVkeHUh?=
KARPAS-422 MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fTXGlEPTB;MD6wOVY2KM7:TR?= MmC2V2FPT0WU
RPMI-8866 NXLsUpVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fTbWlEPTB;MD6wOVcyOiEQvF2= M2\kOHNCVkeHUh?=
SCLC-21H NWjldFk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\DdmdvUUN3ME2wMlA2QDh2IN88US=> MULTRW5ITVJ?
COR-L88 MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjwPHlNUUN3ME2wMlA2QTJ5IN88US=> NYKwRnBMW0GQR1XS
LU-139 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PTOGlEPTB;MD6wOVk5PiEQvF2= M1;F[nNCVkeHUh?=
SF126 MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwME[xN|Mh|ryP M3z5[nNCVkeHUh?=
NCI-H1882 NUjaU3d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwME[0NlQh|ryP MVrTRW5ITVJ?
EW-24 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j3emlEPTB;MD6wOlQ5OyEQvF2= MoPzV2FPT0WU
CP67-MEL M{nyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwME[4NUDPxE1? MXfTRW5ITVJ?
DG-75 NHPzVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzvbodKSzVyPUCuNFY5QTlizszN M3TjO3NCVkeHUh?=
LOXIMVI NXXDPVFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHjTWM2OD1yLkC3NFI5KM7:TR?= M1K0PHNCVkeHUh?=
HH NILOXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLSTWM2OD1yLkC3NVU4KM7:TR?= NHzre2hUSU6JRWK=
K5 M2PVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXt[nRKSzVyPUCuNFczOjZizszN NGC5XIlUSU6JRWK=
EC-GI-10 NYXWSYtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;mZpEzUUN3ME2wMlA4OjV5IN88US=> NHL6c2FUSU6JRWK=
SK-N-DZ M1HKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PnTGlEPTB;MD6wO|MxPyEQvF2= MkewV2FPT0WU
A3-KAW MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH3TWM2OD1yLkC3N|UyKM7:TR?= NWC4VFlpW0GQR1XS
MLMA NYj2T4RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XIfmlEPTB;MD6wO|Q3PSEQvF2= MlztV2FPT0WU
LB996-RCC M3nyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1njUGlEPTB;MD6wO|cxPyEQvF2= MnrPV2FPT0WU
OS-RC-2 MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrRTWM2OD1yLkC3O|Q5KM7:TR?= MWLTRW5ITVJ?
CTB-1 M1zOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfLWG5VUUN3ME2wMlA4QDFizszN MXrTRW5ITVJ?
IST-MES1 M172PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n0UmlEPTB;MD6wO|kyOiEQvF2= Mm\UV2FPT0WU
LS-1034 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTn[lBKSzVyPUCuNFgxOzVizszN NVPrZVc4W0GQR1XS
HT NXXYO5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfsdoJKSzVyPUCuNFgxQDZizszN NY\tWmdSW0GQR1XS
NCI-H2141 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP6dWlCUUN3ME2wMlA5OSEQvF2= MlzZV2FPT0WU
LB2518-MEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjCVWlMUUN3ME2wMlA5OTRzIN88US=> NVPpTIIzW0GQR1XS
GI-ME-N NETwTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnkNZFUUUN3ME2wMlA5PDV{IN88US=> NXTZeVd5W0GQR1XS
TGW Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrVNnhnUUN3ME2wMlA5PjB5IN88US=> Ml;KV2FPT0WU
SK-NEP-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLITWM2OD1yLkC4OlQyKM7:TR?= NWTDNoVjW0GQR1XS
NOMO-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WxSWlEPTB;MD6wPVI4PSEQvF2= NEPqXWpUSU6JRWK=
ES6 NYLEcZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEm1PFkh|ryP NVmzdlM3W0GQR1XS
NCI-H209 Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnNe2lZUUN3ME2wMlA6Pzh4IN88US=> NX3oWmJDW0GQR1XS
GAK NF3EV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknBTWM2OD1yLkGwNVYh|ryP NIDFWYlUSU6JRWK=
BC-1 Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPB[INKSzVyPUCuNVA{PjFizszN NXq4Z|BwW0GQR1XS
KLE MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzqTWM2OD1yLkGwOFQ{KM7:TR?= MVvTRW5ITVJ?
EW-3 M1K3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL5TWM2OD1yLkGwPVgh|ryP M2\MU3NCVkeHUh?=
NKM-1 NI[4[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLCTWM2OD1yLkGxNUDPxE1? MXrTRW5ITVJ?
D-336MG NEPWN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\IbWlEPTB;MD6xNVI1PCEQvF2= M{KybnNCVkeHUh?=
NB69 NV;VNZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknWTWM2OD1yLkGxN|AyKM7:TR?= M2DFdHNCVkeHUh?=
D-263MG NXjRUnhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7lTo1QUUN3ME2wMlEyPzF{IN88US=> NYjpU41OW0GQR1XS
KP-N-YS MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj3So9HUUN3ME2wMlEzOjlzIN88US=> M{jwRXNCVkeHUh?=
NCI-H1155 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzmTWM2OD1yLkGyOVU5KM7:TR?= NHTPfFVUSU6JRWK=
BOKU MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK0ZWdKSzVyPUCuNVI2PzlizszN MVzTRW5ITVJ?
LAMA-84 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDFTWM2OD1yLkGyPVkh|ryP NHLrcVhUSU6JRWK=
Raji NVHDeFFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLwTWM2OD1yLkGzNVE4KM7:TR?= MXXTRW5ITVJ?
LU-65 M3vCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMUOzNFch|ryP NXHS[YF3W0GQR1XS
NCI-H187 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMUO5NlQh|ryP MYTTRW5ITVJ?
GCIY MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLrTWM2OD1yLkG0PVAyKM7:TR?= NEfObmNUSU6JRWK=
NCI-H2107 NXHl[VRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTHSGdKSzVyPUCuNVUxQCEQvF2= NGiyWVZUSU6JRWK=
NCI-H1522 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\NTWM2OD1yLkG1NlY3KM7:TR?= MnvpV2FPT0WU
NB6 NV7Bc4xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;wTWM2OD1yLkG1OlI{KM7:TR?= NGHXVINUSU6JRWK=
EM-2 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3iwbGlEPTB;MD6xOVcxPiEQvF2= MV\TRW5ITVJ?
HCC2218 M4rmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3HeoFMUUN3ME2wMlE2QThizszN MofuV2FPT0WU
NCI-H748 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\O[I1KSzVyPUCuNVY{PzZizszN NHfYco5USU6JRWK=
MS-1 M4HlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HIfWlEPTB;MD6xOlU{PyEQvF2= MUXTRW5ITVJ?
NB5 NFrEV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG5W3F{UUN3ME2wMlE3PTl5IN88US=> M2L0SnNCVkeHUh?=
OMC-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLsbZdKSzVyPUCuNVY3QDhizszN Mn3PV2FPT0WU
NCI-H345 M2LUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLaTWM2OD1yLkG2PVI5KM7:TR?= M{LQPXNCVkeHUh?=
L-428 NEXiUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXEWXdqUUN3ME2wMlE3QTR3IN88US=> NW[5OFcyW0GQR1XS
SCH NXHMSGFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{GyTWlEPTB;MD6xPFY5PSEQvF2= NFW3OplUSU6JRWK=
NCI-H1417 NU\tcIxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXDNXJUUUN3ME2wMlE6OjJ5IN88US=> NVf1VoY5W0GQR1XS
COLO-320-HSR NEHsfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fP[2lEPTB;MD6xPVU{OiEQvF2= NIXaNpBUSU6JRWK=
BT-474 MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLJTWM2OD1yLkKwPFkzKM7:TR?= Mnm1V2FPT0WU
GDM-1 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fkOGlEPTB;MD6yNVk4OSEQvF2= Mm\mV2FPT0WU
NCI-H2196 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HoRmlEPTB;MD6yNlI{PSEQvF2= MVfTRW5ITVJ?
KP-N-RT-BM-1 NUXmWlk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;XRWlEPTB;MD6yNlM1QSEQvF2= M4m4WnNCVkeHUh?=
KNS-81-FD M2\lZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMkK5OVgh|ryP NGrPeW5USU6JRWK=
COLO-668 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XYe2lEPTB;MD6yN|Y4PSEQvF2= Ml;LV2FPT0WU
C2BBe1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrGSm1KSzVyPUCuNlY4PDdizszN MYfTRW5ITVJ?
Ramos-2G6-4C10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL4TWM2OD1yLkK2PVU1KM7:TR?= MWPTRW5ITVJ?
CAS-1 MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMkewPVYh|ryP NETnc2VUSU6JRWK=
GOTO M2nVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX2U5NXUUN3ME2wMlI4QDl2IN88US=> NX3zV2V{W0GQR1XS
LP-1 M2fDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;QTGlEPTB;MD6yPFA2PyEQvF2= M2jKdHNCVkeHUh?=
NCI-SNU-1 NGOw[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\SNIdHUUN3ME2wMlI6PDJ{IN88US=> M2rMR3NCVkeHUh?=
EB-3 M4npOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMkm5O|kh|ryP NEHiSGZUSU6JRWK=
MHH-NB-11 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwM{C0NFIh|ryP MkTuV2FPT0WU
SK-N-FI MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfSVWJSUUN3ME2wMlMyPjl{IN88US=> MlriV2FPT0WU
HCC2157 NEnId|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nsWGlEPTB;MD6zN|kyOyEQvF2= NGf4dmtUSU6JRWK=
SIMA MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PSbGlEPTB;MD6zOFU5OSEQvF2= NULEN|JyW0GQR1XS
MDA-MB-134-VI M4rQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj3S|hSUUN3ME2wMlM3QTJ6IN88US=> MW\TRW5ITVJ?
NCI-H1694 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT3OmhKSzVyPUCuN|ch|ryP MX7TRW5ITVJ?
EHEB MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:1T4dDUUN3ME2wMlM6ODh3IN88US=> NVnVNoFbW0GQR1XS
U-266 NUi1cpJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrvXHBoUUN3ME2wMlM6QDR4IN88US=> NX;aeIN3W0GQR1XS
LC-1F MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jxT2lEPTB;MD60N|c3PSEQvF2= NX3FdHM3W0GQR1XS
SHP-77 NILRV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK2TWM2OD1yLkS3PFU2KM7:TR?= NHrhRplUSU6JRWK=
LS-513 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfYTWM2OD1yLkS5N|A4KM7:TR?= MVzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 Paclitaxel单独处理 BC-V 和 BC-ER肿瘤的抑制定额分别为49.78 和 51.23%。20 mg/kg Paclitaxel处理6个周期,显著降低Ki-67阳性细胞百分比,BC-V肿瘤中降到20.4%,BC-ER 肿瘤中降到25.1%。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

+ 展开
  • Cell lines: 细胞,包括人类新生儿皮肤微血管内皮细胞(HMVECs), 人脐静脉内皮细胞(HUVECs), 人脐动脉内皮细胞 (HUAVECs), 正常人类星形胶质细胞(NHAs), 正常人体皮肤成纤维细胞(NHDFs), 正常人表皮角质形成细胞(NHEKs), 人类乳腺上皮细胞(HMEpCs), 人前列腺上皮细胞(PrEpCs) 和人脐动脉平滑肌细胞(UASMCs)
  • Concentrations: 0.1 pM-100 pM
  • Incubation Time: 72 小时
  • Method:

    培养细胞,包括人类新生儿皮肤微血管内皮细胞(HMVECs), 人脐静脉内皮细胞(HUVECs), 人脐动脉内皮细胞 (HUAVECs), 正常人类星形胶质细胞(NHAs), 正常人体皮肤成纤维细胞(NHDFs), 正常人表皮角质形成细胞(NHEKs), 人类乳腺上皮细胞(HMEpCs), 人前列腺上皮细胞(PrEpCs) 和人脐动脉平滑肌细胞(UASMCs)。在96孔板中使用6和12通道的细胞进行增殖。细胞按每孔3000–5000个细胞接种,然后粘附4小时。Paclitaxel在培养基中稀释,然后按一式四份加到孔中,细胞温育3天,然后加入MTS 试剂,然后定量测量每孔中的活细胞。


    (Only for Reference)
动物实验:

[5]

+ 展开
  • Animal Models: 携带BC-V 和 BC-ER肿瘤的雌性20-22 g 纯和裸鼠
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+5% Tween 80+ddH2O
2.5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 853.91
化学式

C47H51NO14

CAS号 33069-62-4
稳定性 powder
in solvent
别名 NSC 125973

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03694002 Recruiting Locally Advanced Thymic Carcinoma|Metastatic Thymic Carcinoma|Recurrent Thymic Carcinoma|Unresectable Thymic Carcinoma Southwest Oncology Group|National Cancer Institute (NCI) August 9 2018 Phase 2
NCT03275818 Recruiting Tumor Desmoplastic Small Round Cell Adult|Tumor Desmoplastic Small Round Cell Childhood|Sarcoma Ewing|Sarcoma|Desmoid Grupo Espanol de Investigacion en Sarcomas May 9 2017 Phase 2
NCT03057600 Active not recruiting Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer Calithera Biosciences Inc May 9 2017 Phase 2
NCT02775435 Active not recruiting Non-small Cell Lung Cancer Merck Sharp & Dohme Corp. June 9 2016 Phase 3
NCT02181634 Completed Cholangiocarcinoma PrECOG LLC.|Celgene Corporation December 9 2014 Phase 2
NCT02415023 Completed Gastric Cancer Hutchison Medipharma Limited November 9 2014 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 问题 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Paclitaxel | Paclitaxel供应商 | 采购Paclitaxel | Paclitaxel价格 | Paclitaxel生产 | 订购Paclitaxel | Paclitaxel代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID